Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gefitinib
Drug ID BADD_D01008
Description Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Indications and Usage For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
Marketing Status Prescription; Discontinued
ATC Code L01EB01
DrugBank ID DB00317
KEGG ID D01977
MeSH ID D000077156
PubChem ID 123631
TTD Drug ID D09XZB
NDC Product Code 54245-1359; 65344-0029; 54893-0036; 63850-8070; 53104-7700; 73377-128; 0310-0482; 61200-002; 46708-880; 68554-0060
Synonyms Gefitinib | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide | Iressa | ZD1839 | ZD 1839
Chemical Information
Molecular Formula C22H24ClFN4O3
CAS Registry Number 184475-35-2
SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Acne23.02.01.0010.001066%Not Available
Acute respiratory failure22.02.06.001; 14.01.04.0040.000278%Not Available
Alanine aminotransferase increased13.03.01.0030.003197%
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.000533%Not Available
Alveolitis22.01.01.001--Not Available
Amblyopia06.02.01.001--Not Available
Amnesia17.03.02.001; 19.20.01.0010.001066%
Anaemia01.03.02.001--
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anorectal disorder07.03.01.001--Not Available
Aphasia19.21.01.001; 17.02.03.0010.000799%
Arrhythmia02.03.02.001--Not Available
Arteriosclerosis coronary artery24.04.04.012; 02.02.01.0110.000139%Not Available
Aspartate aminotransferase increased13.03.01.0060.001332%
Asthenia08.01.01.001--Not Available
Atelectasis22.01.02.0010.000533%
Atrial fibrillation02.03.03.002--
B-cell lymphoma16.28.01.001; 01.15.01.0010.000139%Not Available
Back pain15.03.04.005--
Bladder cancer16.08.01.001; 20.03.04.0010.000278%Not Available
Bladder pain20.02.02.001--Not Available
Blepharitis23.03.04.012; 06.04.04.001--Not Available
Blood bilirubin increased13.03.01.0080.000533%
Blood creatinine increased13.13.01.004--
Blood glucose increased13.02.02.002--Not Available
Blood pressure decreased13.14.03.0020.000533%Not Available
Body temperature increased13.15.01.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 10 Pages